[go: up one dir, main page]

DE602005015256D1 - Hetero-oligomere hiv-hüllproteine - Google Patents

Hetero-oligomere hiv-hüllproteine

Info

Publication number
DE602005015256D1
DE602005015256D1 DE602005015256T DE602005015256T DE602005015256D1 DE 602005015256 D1 DE602005015256 D1 DE 602005015256D1 DE 602005015256 T DE602005015256 T DE 602005015256T DE 602005015256 T DE602005015256 T DE 602005015256T DE 602005015256 D1 DE602005015256 D1 DE 602005015256D1
Authority
DE
Germany
Prior art keywords
hiv
different
heterotrimer
env glycoprotein
isolates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005015256T
Other languages
English (en)
Inventor
Leonidas Stamatatos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seattle Biomedical Research Institute
Original Assignee
Seattle Biomedical Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Biomedical Research Institute filed Critical Seattle Biomedical Research Institute
Publication of DE602005015256D1 publication Critical patent/DE602005015256D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602005015256T 2004-12-29 2005-12-28 Hetero-oligomere hiv-hüllproteine Active DE602005015256D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64032904P 2004-12-29 2004-12-29
PCT/US2005/047244 WO2006071933A2 (en) 2004-12-29 2005-12-28 Hetero-oligomeric hiv envelope proteins

Publications (1)

Publication Number Publication Date
DE602005015256D1 true DE602005015256D1 (de) 2009-08-13

Family

ID=36615506

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005015256T Active DE602005015256D1 (de) 2004-12-29 2005-12-28 Hetero-oligomere hiv-hüllproteine

Country Status (9)

Country Link
US (1) US20080248063A1 (de)
EP (2) EP2088155A1 (de)
CN (1) CN101094862A (de)
AT (1) ATE435234T1 (de)
DE (1) DE602005015256D1 (de)
DK (1) DK1831247T3 (de)
ES (1) ES2328507T3 (de)
WO (1) WO2006071933A2 (de)
ZA (1) ZA200706186B (de)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL46110C (de) 1936-08-07 1939-02-15
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US6716429B1 (en) * 1997-10-01 2004-04-06 Dana-Farber Cancer Institute, Inc. Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp 41 glycoprotein ectodomain
FR2781676B1 (fr) * 1998-07-31 2004-04-02 Pasteur Merieux Serums Vacc Trimere du produit d'expression du gene env de hiv
EP1214333A4 (de) * 1999-09-17 2005-01-19 Dana Farber Cancer Inst Inc STABILISIERTE LöSLICHE GLYKOPROTEINTRIMERE
US6761902B2 (en) 1999-12-30 2004-07-13 Dana-Farber Cancer Institute, Inc. Proteoliposomes containing an integral membrane protein having one or more transmembrane domains
EP1461079B8 (de) * 2001-09-06 2012-03-14 Progenics Pharmaceuticals, Inc. Mutanten von hüllglykoproteinen des human immunodeficiency virus und deren verwendung

Also Published As

Publication number Publication date
CN101094862A (zh) 2007-12-26
WO2006071933A2 (en) 2006-07-06
WO2006071933A3 (en) 2007-02-15
HK1107998A1 (en) 2008-04-25
ZA200706186B (en) 2008-06-25
US20080248063A1 (en) 2008-10-09
EP1831247A2 (de) 2007-09-12
DK1831247T3 (da) 2009-10-12
ES2328507T3 (es) 2009-11-13
ATE435234T1 (de) 2009-07-15
EP2088155A1 (de) 2009-08-12
EP1831247B1 (de) 2009-07-01

Similar Documents

Publication Publication Date Title
Yang et al. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins
DK1402015T3 (da) Opløseligt kompleks omfattende et retroviralt overfladeglycoprotein og FkpA eller SlyD
JP2019501882A5 (de)
MY145614A (en) Vaccine
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
DE69534569D1 (de) Hiv-1- und hiv-2-peptide zur hemmung von mit membranfusionen in zusammenhang stehenden phänomenen, einschliesslich der übertragung von hiv
BRPI0511982A (pt) compostos antiviróticos heterocìclicos
JP2017501986A5 (ja) 二重特異性hiv−1中和抗体
ES2307496T4 (es) Composiciones de vacuna, antígenos y péptidos de VIH
WO2007149491A3 (en) Soluble stabilized trimeric hiv env proteins and uses thereof
WO2020252393A8 (en) Compositions and methods for the treatment of human immunodeficiency virus
King et al. The structural basis for filovirus neutralization by monoclonal antibodies
WO2008151633A3 (en) Vectors for vaccines against lentivirus infections
Zhuang et al. Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways
ATE509942T1 (de) Nichtproteolysierbare oligopeptide, die das glycoprotein gp41 von hiv inhibieren
WO2002020555A3 (en) Hiv peptides from tat, rev and wef conserved regions and their application as e.g.vaccine components
DE602005015256D1 (de) Hetero-oligomere hiv-hüllproteine
ES2673972T3 (es) Formas solubles de la glicoproteína G de los virus hendra y nipah
JP2006503849A5 (de)
WO2004108886A3 (en) Anti-hiv-1 compounds based upon a conserved amino acid sequence shared by gp160 and the human cd4 protein
WO2002064154A3 (en) Methods and compositions for inhibiting hiv-coreceptor interactions
Setiyaningsih et al. Sequence analysis of mRNA transcripts encoding Jembrana disease virus Tat-1 in vivo
WO2010135663A3 (en) Compositions and methods for the detection of hiv-1/hiv-2 infection
RU2000106709A (ru) Пептиды-имитаторы консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5
WO2004041194A3 (en) Inhibition of hiv-1 replication

Legal Events

Date Code Title Description
8364 No opposition during term of opposition